Kidney Week 2025: ORIGIN 3 Sets the Stage for Atacicept in IgA Nephropathy Patrick Campbell

Published Date: 21 Nov 2025

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot